Sign up
Pharma Capital

ImmuPharma confident of topline results from Phase III Lupuzor trial this quarter

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM), tells Proactive the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, their lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.

He adds that 200 patients have now been successfully recruited and dosed, with top line results remaining on track to be reported in the first quarter of 2018.


View full IMM profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.